Chlamydia trachomatis is an obligate intracellular bacterium that infects the mucosal epithelium of the eye and the genital tract. C. trachomatis ocular infections can lead to trachoma, the single most important cause of preventable blindness worldwide (5) . Attempts to control trachoma in developing countries by the use of widespread antibiotic therapy have not succeeded (4) . In the industrialized world, chlamydial infections of the urogenital tract are a leading cause of sexually transmitted disease. Because these infections are frequently asymptomatic, treatment may not be sought until serious sequelae have developed. The consequences are particularly severe in women, since genital-tract infection can often lead to pelvic inflammatory disease, ectopic pregnancy, or tubal infertility (10) .
An effective vaccine would significantly enhance efforts to control both trachoma and the highly prevalent sexually transmitted infections. Because of the immunopathological nature of chlamydial disease, attempts at vaccination with the intact bacterium have led to more severe disease in some individuals, with only limited protection from reinfection in others (7) . In human trials, protective immunity is serovariant specific, and numerous animal models have shown that this protective response is T-cell dependent (11) . Since there are over 15 serological variants of C. trachomatis and because there exists the potential for eliciting immunopathological responses, a subunit approach to vaccine development may be the most useful.
The serovar-specific protective antibody responses are directed at the surface-exposed, major outer membrane protein (MOMP) of C trachomatis (3) , and MOMP has thus been the primary focus of vaccine-based research. Sequence analysis of MOMP has revealed that amino acid sequence variation between isolates accounts for the antigenic diver-* Corresponding author. sity of this pathogen (13) . There are four sequence-variable segments (VS) of the molecule, flanked by five sequenceconserved segments. Monoclonal antibody mapping has determined that complement-independent, neutralizing, type-specific responses are directed at the first and second VS (2, 14, 16) .
We recently used recombinant MOMP fusion peptides in an in vivo functional assay to define regions of the molecule capable of eliciting T-cell help for the production of protective antibody (1) and found that with BALB/c mice, a single region of MOMP encompassing the third VS (VS3) is particularly effective in these assays. In the present study, we produced short-term T-cell lines to evaluate MOMP peptides in an in vitro proliferation format. Of the nine recombinant peptides delineating the MOMP protein, only the peptide encompassing VS3 elicited proliferation with chlamydiaspecific BALB/c T-cell lines. Further, we identified that a sequence-conserved region of the peptide was stimulatory in these assays. These results demonstrate a marked correlation between in vivo analysis of T-cell help and evaluation by short-term T-cell line proliferation in vitro.
MATERUILS AND METHODS
Growth and purification of C. trachomatis. Ocular strains of C. trachomatis, B/TW-5/OT and C/TW-3/OT, have been described previously (8 (1) . The sequence of the VS3 peptide is shown, as well as those of the smaller peptides used for mapping of T-cell recognition sites within VS3. Stars indicate amino acid differences between the serovar B and serovar C sequences. The identities of VS3 peptides used in subsequent figures are in parentheses. Fig. 1 ) and the glutathione-Stransferase (GST) control were prepared and purified as previously described for nine MOMP fusion peptides (1, 12) .
MOMP purification. Purified serovar B or C EBs were boiled in sodium dodecyl sulfate (SDS) sample buffer containing 5% ,3-mercaptoethanol, and proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE). MOMP was localized by Coomassie brilliant blue staining of a vertical gel strip. The MOMP band was excised from the unstained gel, ground into a fine particulate, and placed in phosphate-buffered saline overnight. The MOMP eluted in this manner was analyzed for purity by SDS-PAGE and quantitated by Lowry protein determination.
Preparation of short-term MOMP-specific T-celi lines. Female BALB/c/by mice aged 6 to 8 weeks were obtained from Jackson Laboratories (Bar Harbor, Maine). The mice were immunized by subcutaneous injection with 10 ,ug of MOMP from either serovar B or serovar C emulsified in complete Freund's adjuvant. Popliteal lymph nodes were removed from three mice 10 days after immunization, and single-cell suspensions were prepared by filtering through a fine-mesh metal screen. Lymph node cells (4 x 106/ml) were cultured in 75-cm2 flasks in RPMI 1640 with 1 mM 2-ME, 1 ,uM glutamine, 2 puM sodium pyruvate, 100 U of penicillin per ml, 100 p,g of streptomycin per ml, and 0.5% mouse serum at 37°C in an atmosphere of 5% CO2. Cells derived from mice immunized with serovar B MOMP were cultured with 5 pug of serovar B EBs or 2 ,ug of GST-VS3-B (serovar B sequence) per ml. Cells derived from mice immunized with serovar C MOMP were cultured with 5 ,ug of serovar C EBs or 2 p,g of GST-VS3-C (serovar C sequence) per ml. After 4 days of stimulation culture with specific antigen, T cells (105/ml) were cultured for 7 days with 106 accessory cells per ml in the absence of antigen and with 7% rat concanavalin A-stimulated medium and 10% fetal bovine serum instead of mouse serum (rest culture). Viable cells were isolated for assay by Ficoll separation. Fluorescence-activated cell sorter analysis demonstrated that T-cell lines prepared in this manner were >90% CD4+. Accessory cells were prepared by irradiation (3,000 rads with 137Cs) of single-cell suspensions of syngeneic spleen cells.
T-cell proliferation assay. Ficoll-purified T cells obtained following 11 days of culture, irradiated accessory cells, and antigens were diluted in RPMI 1640 with 1 ,M glutamine, 2 ,uM sodium pyruvate, 100 U of penicillin and 100 p.g of streptomycin per ml, and 10% fetal bovine serum. A 100-pl volume of 10 T cells and 107 accessory cells per ml were placed in 96-well U-bottom plates. A 100-pl volume of medium with various concentrations of either fusion protein or purified EBs was added to the wells. Antigens were tested in triplicate wells. After 4 days of incubation, 0.5 pCi of tritiated thymidine ([3H]TdR) was added to each well and incubated overnight. The cells were harvested onto filters with a cell harvester, and [3H]TdR incorporation was measured in a liquid scintillation counter. The results are expressed as stimulation indices (SI), where SI = counts per minute in test well/counts per minute in medium control well.
RESULTS
In vitro mapping of MOMP T-cell recognition sites. BALB/c mice were immunized with purified MOMP, and short-term T-cell lines were produced by 4 days of stimulation with intact organism followed by 7 days of culture in the absence of antigen. These cells, now predominantly CD4+, were used in a T-cell proliferation assay to measure the stimulatory capacity of nine MOMP fusion peptides (Fig. 1) . In this assay format, only the peptide encompassing VS3 was stimulatory (Fig. 2) . In contrast, we had previously tested the ability of these nine MOMP fusion peptides to elicit proliferation of T cells derived from the spleens of chlamydia-infected mice. In these primary-culture assays, several of the MOMP peptides generated proliferative responses (1 primary spleen cells. However, in an in vivo functional assay in which mice are immunized with each of the nine fusion peptides and then challenged with intact organism, the VS3 peptide was significantly more effective in eliciting T-cell help for the production of anti-EB antibodies than the other eight MOMP peptides (1) . Therefore, the results with T-cell lines correspond more directly to the in vivo functional data than analysis of primary spleen cell cultures.
Evaluation of VS3 sequence diversity. To evaluate the potential role of sequence diversity in the T-cell response to the GST-VS3 fusion peptide, T-cell lines were developed from mice immunized with either serovar B MOMP or serovar C MOMP and stimulated with the intact organism of the homologous serovar. Proliferative responses of these T-cell lines were then tested with VS3 fusion peptides with amino acid sequences corresponding to either serovar B or serovar C. Serovar B and serovar C were chosen for evaluation, since they are the most sequence divergent and antigenically distinct of the C. trachomatis serovariants. As demonstrated in Fig. 3 , whether the T cells were selected with serovar B or serovar C antigen, both the VS3-B and the VS3-C peptides stimulated T-cell proliferation. Thus, sequence diversity within the VS3 fragment did not significantly influence T-cell recognition of this peptide in BALB/c mice.
Mapping of T-cell recognition sites within VS3. The assay format with short-term T-cell lines was used to map the T-cell determinants within the large VS3 fusion peptide. Fusion peptides that corresponded to the conserved aminoterminal portion of GST-VS3 and the more variant sequence carboxyl-terminal portion were designed (Fig. 1) . The variant-sequence region of the VS3 fragment (peptides KE and AE) was not capable of stimulating EB-selected T cells, whereas the more conserved portion (GG) elicited T-cell proliferation (Fig. 4) . However, the smaller GG fragments were not as effective a T-cell antigen as the full-size (GE) GST-VS3 fragment. Optimal recognition may require the larger GE fragment, since reactivity to this peptide may be due to the presence of more than one T-cell determinant, or require processing sites not available in the smaller fusion peptides. Analysis of the KE and GG fragments in an in vivo functional assay was consistent with this result; only the conserved GG fragment was capable of priming for a MOMP-specific antibody response in BALB/c mice after challenge with EBs (unpublished observation).
VS3-specific T-cell lines. We also evaluated whether T-cell lines selected with the GST-VS3 fusion peptide could be used for T-cell-determinant mapping as effectively as T cells selected with EBs, since the fusion peptide would not be processed in the same fashion as the native MOMP. T cells derived from MOMP-immunized mice were stimulated in vitro with purified VS3 fusion peptide rather than intact organism. These lines were tested against intact organism and each of the VS3 fragments. The results are shown in Fig.  5 . It was significant that T-cell lines selected by using the VS3 fragment proliferated strongly in response to chlamydiae, emphasizing the importance of this region as a T-cell recognition sequence in the context of processing of the entire bacterium. In addition, the observed pattern of reactivity to GST-VS3 and the two fragments (KE and GG) was identical to that seen with lines directed against the intact organism. Thus, fine-mapping studies may be facilitated by using cloned peptides to prepare T-cell lines.
DISCUSSION
The MOMP of C. trachomatis is the most promising candidate antigen for designing a subunit vaccine for chlamydia infection. Protection is known to be serovariant specific, and serovar-specific antibodies to MOMP neutralize infectivity in vitro and in vivo (16) . An (1, 15) . Significantly, short-term chlamydiaspecific T-cell lines in this system restricted the response to the region of MOMP containing VS3. The restricted response of the T-cell lines to one peptide (i.e., VS3) compared with the response in primary cultures to several peptides (1, 15) was a surprising finding, and this suggests that VS3 represents an immunodominant T-cell determinant (9) . We have previously found that this peptide, VS3, has the ability to stimulate T cells in vivo that provide help to MOMPspecific B cells (1) . Thus, there is a striking correlation between the in vitro proliferation of these lines and previously described in vivo analysis of T-cell help. This correlation between functional assays and in vitro evaluation provides a valuable tool for the analysis of T-cell determinants for vaccine development.
Gajewski et al. (6) showed that different Th subsets proliferate optimally to different antigen-presenting cell populations and, in particular, that Th2 cells proliferate in response to B cells, whereas Thl cells proliferate optimally to radioresistant cell populations. The predominant antigenpresenting cell in the primary spleen cell cultures is the radioresistant dendritic cell or macrophage with some B-cell contamination of the nylon wool-purified T cells. In the short-term T-cell lines, high numbers of MOMP-specific lymph node-derived B cells are present during the stimulation culture. The presence of a large population of specific B cells may select in vitro for the same population of T helper cells that are effective in vivo for providing T-cell help for the production of antibody. The ability of a particular determinant to be processed and presented effectively by MOMP-specific B cells may be the factor that results in the relationship between the in vitro proliferative response of short-term lines and the in vivo functional analysis. An additional selection factor may occur, because EBs are used during in vitro stimulation and constraints in the processing of native organism-associated MOMP versus denatured MOMP may limit the response to certain peptides.
The importance of VS3 as a T-helper determinant needs to be evaluated by assessment of its function in multiple murine haplotypes and evaluation of sequence diversity recognition in each of these strains. Preliminary results with C3H mice by the in vivo approach demonstrated that these mice recognize the variant-sequence (KE) portion of VS3. However, these assays require large numbers of mice; therefore, the number of variables that can be tested is limited. Analysis of sequence variability in the C3H mouse response and the fine specificity of T-cell determinants with other strains of mice representing a variety of haplotypes should be greatly facilitated by the use of T-cell lines rather than in vivo assays. Thus, the short-term cell lines should facilitate the analysis of multiple murine major histocompatibility complex haplotypes and permit concurrent finer mapping of the functionally important determinants in T-cell recognition. Preliminary data from one experiment with a T-cell line derived from C3H mice showed strong proliferation to the VS3 peptide. This suggests that recognition of T-cell determinants within the VS3 peptide is not restricted only to the H-2d haplotype. If the correlation between the proliferation of short-term lines and functional T-cell help could be demonstrated in humans by using peripheral blood lymphocytes, this would provide a valuable means to analyze the human T-cell response to chlamydia antigens and allow a safe and relatively noninvasive means to evaluate large numbers of individuals for their capacity to respond to vaccine constructs prior to more-risky studies involving immunization of human subjects.
